Cytomaite II – Uncovering Prognostic Biomarkers in Leukemia with Explainable AI
Microscopy based evaluation of drug response profiles in NPM1c acute myeloid leukemia
Cytomaite Development of artificial intelligence-driven tools based on cytomorphological analysis for diagnostic and outcome prediction of patients with acute hematological diseases
B-C-ALL- Colony counting for B-cell acute lymphocytic leukemia
AI-compatible platform for automated therapeutic target discovery to overcome acquired drug resistance in leukemia
Using artificial intelligence to decipher and manipulate cellular growth patterns in acute myeloid leukemia (AI@AML)
Development of a machine-learning approach for leukemia cell – mcroenvironment interactions
Funded By Mertelsmann Foundation
The Mertelsmann Foundation has made improving the fight against cancer with the help of innovative methods its main concern. To this end, it brings together cancer research and artificial intelligence. In doing so, it relies on interdisciplinary collaboration between experimental and clinical oncology, artificial intelligence and philosophy.